ARMMS-T2D: early surgery, before insulin, gives the best chance of lasting remission

Design

Long-term follow-up of four pooled randomised trials

Population

262 adults with type 2 diabetes, mean BMI 36.4, HbA1c 8.5%

Primary outcome

Diabetes remission and relapse, median 11-year follow-up

Effect

Remission 58% with surgery vs 3% with medical-lifestyle care

ARMMS-T2D followed 262 people with type 2 diabetes from four randomised trials that compared metabolic-bariatric surgery with intensive medical-lifestyle care. At entry the mean age was 50, BMI 36.4 and HbA1c 8.5%. Over a median of 11 years, and up to 14, 58% of the 166 surgical patients reached remission (HbA1c below 6.5% on no glucose-lowering drugs) against 3% of the 96 medical patients.

In multivariable analysis, shorter diabetes duration, not using insulin, and greater weight loss at one year predicted remission. Among those who did remit after surgery, longer diabetes duration and more glucose-lowering drug classes at baseline predicted relapse.

The finding turns surgery from a last resort into a timing question. People with shorter diabetes and preserved beta-cell function gain the most, so the conversation is best had before insulin rather than after it. Predictor analyses are hypothesis-generating, and the sample is small, but the direction is consistent across both remission and relapse.

• Raise metabolic surgery early with eligible patients who have obesity and type 2 diabetes, not only after insulin has started.
• Record diabetes duration and number of drug classes at referral; both predicted relapse after remission.
• Weight lost in the first year after surgery is an early guide to who will remit.
• Counsel patients with long-standing, insulin-treated diabetes that surgery may help, but lasting remission is less likely.
• In India, the Asian BMI thresholds for metabolic surgery bring this discussion forward for many patients.

Why it matters

Surgery is usually offered once everything else has failed — the point at which it is least likely to produce remission.

Don't overread it

The predictors come from an exploratory analysis of 262 people; they guide counselling rather than set referral rules.

The statistics, in plain English

58% versus 3% is a randomised comparison and very unlikely to be chance. The predictor findings are within-trial associations, so they show who did better, not that changing those factors would change the result.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.